A hidden enzyme gives up breast cancer's escape plan

When breast cancer outsmarts treatment, it may be following orders from an enzyme nobody suspected. Naama Kanarek and Taru Muranen at Boston Children's caught FAH — thought to be a humble metabolic worker — moonlighting inside the nucleus of resistant tumor cells, driving resistance to standard CDK4/6 drugs. Block its partner CDK9, and the resistance reverses. For the most common breast cancer subtype, that's a brand-new door, published in Science Advances.